Kodiak Sciences (NASDAQ:KOD) Hits New 52-Week High - Here's What Happened

Key Points

• Kodiak Sciences stock hit a new 52-week high, trading as high as $46.67 and last at $44.63 during mid-day trading, up from a prior close of $43.11 on strong volume.
• Analysts have become more bullish recently—UBS raised its target to $80 and HC Wainwright to $58—leaving a consensus rating of Moderate Buy with a $35.43 price target.
• Despite the rally, Kodiak remains a clinical‑stage ophthalmic biotech (lead candidate KSI‑301) that missed quarterly EPS estimates (‑$1.04 vs. ‑$1.02), has a $2.63B market cap, and about 89% institutional ownership.

Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $46.67 and last traded at $44.6270, with a volume of 270440 shares changing hands. The stock had previously closed at $43.11.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. UBS Group lifted their target price on shares of Kodiak Sciences from $50.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, March 27th. HC Wainwright reiterated a "buy" rating and issued a $58.00 target price (up from $38.00) on shares of Kodiak Sciences in a research note on Friday, March 27th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kodiak Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.43.

Kodiak Sciences Stock Down 1.5%

The firm has a market cap of $2.63 billion, a price-to-earnings ratio of -9.83 and a beta of 2.39. The business's fifty day moving average is $28.04 and its two-hundred day moving average is $24.04.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). Research analysts forecast that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Institutional Trading of Kodiak Sciences

Institutional investors and hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC raised its position in shares of Kodiak Sciences by 1,221.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company's stock valued at $28,000 after acquiring an additional 916 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Kodiak Sciences during the 4th quarter valued at $29,000. Headlands Technologies LLC raised its position in shares of Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock valued at $30,000 after acquiring an additional 5,815 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Kodiak Sciences in the fourth quarter worth $72,000. Finally, Strs Ohio bought a new position in shares of Kodiak Sciences during the fourth quarter worth $87,000. Institutional investors own 89.06% of the company's stock.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.